Brought to you by 
BioMarin raises $67.5mm by selling priority review voucher to Sanofi/Regeneron
21 Sep 2020
Executive Summary
Rare disease company BioMarin Pharmaceutical Inc.’s Irish subsidiary BioMarin GALNS Ltd. raised $67.5mm in cash by selling its priority review voucher (PRV) to Sanofi and Regeneron Pharmaceuticals Inc. (via Regeneron Ireland), which equally split the cost.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Priority Review Voucher (PRV) Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioMarin raises $67.5mm by selling priority review voucher to Sanofi/Regeneron
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice